Author:
Mahoney Kathleen M.,Freeman Gordon J.,McDermott David F.
Subject
Pharmacology (medical),Pharmacology
Reference91 articles.
1. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
2. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012
3. Safety and tumor responses with lambrolizumab (anti-pd-1) in melanoma;Hamid;N Engl J Med,2013
4. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J Clin Oncol,2014
5. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013
Cited by
481 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献